The role of mesothelin in tumor progression and targeted therapy

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Mesothelin is a cell surface protein highly expressed in various cancers, including mesothelioma, ovarian, pancreatic, and cholangiocarcinoma.
• Its expression suggests mesothelin is a viable target for antibody-based cancer therapies.
• Current clinical trials are evaluating mesothelin-targeting agents like the SS1P immunotoxin and MORAb-009 (amatuximab).

Purpose of the Study:

• To review the role of mesothelin in cancer progression.
• To provide insights into mesothelin-targeted cancer therapies.
• To highlight novel therapeutic strategies involving mesothelin.

Main Methods:

• Review of recent studies on mesothelin's function in cancer.
• Analysis of mesothelin's interactions with MUC16 (CA125).
• Examination of mesothelin's involvement in the NF-κB signaling pathway.
• Assessment of mesothelin's role in chemotherapy resistance.
• Identification of new human monoclonal antibodies via phage display technology.

Main Results:

• Mesothelin facilitates peritoneal tumor metastasis through MUC16 interaction.
• Mesothelin promotes cancer cell survival and proliferation via NF-κB signaling.
• Mesothelin expression confers resistance to chemotherapy agents like TNF-α and paclitaxel.
• Novel human monoclonal antibodies targeting mesothelin have been developed.

Conclusions:

• Mesothelin plays a significant role in cancer progression through multiple mechanisms.
• Its cancer-specific expression makes it an attractive target for antibody-based therapies.
• Emerging monoclonal antibodies targeting mesothelin hold potential for innovative cancer treatments.